MMRF PRESS RELEASES
Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations at 46th Annual American Society of Clinical Oncology (ASCO) Annual Meeting
Norwalk, CT — June 1, 2010
The Multiple Myeloma Research Consortium (MMRC) today announced the presentation of studies conducted through its clinical sites in collaboration with industry partners, Onyx Pharmaceuticals and Bristol-Myers Squibb, in evaluating promising new therapeutic agents for multiple myeloma at the 46th Annual American Society of Clinical Oncology (ASCO) Meeting, June 4-8, 2010 in Chicago, IL. The oral presentations will include updated data on MMRC-associated studies of potential drugs in the treatment of multiple myeloma.
“We are very excited to have data from these collaborative studies presented as part of the Clinical Science Symposium on Novel Therapies for Myeloma as well as the Oral Abstract Session at this year’s ASCO. These abstracts demonstrate the MMRC’s commitment to working side-by-side with its industry partners, and to implementing measures to enhance quality, speed and efficiency of clinical trials conducted by our Consortium clinical sites. We aim to ensure that promising new drug candidates are making progress in drug development since patients have needs for new therapeutic options,” said Susan Kelley, MD, Chief Medical Officer of the MMRC.
Presentations of data from trials conducted within the MMRC:
Saturday, June 5, 2010; Clinical Science Symposium: Lymphoma and Plasma Cell Disorders Results of an Ongoing Open-Label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (MM)
- Dr. Ravi Vij, Washington University School of Medicine
- Abstract #8000
- 4:30-6:00 p.m., E354a
Saturday, June 5, 2010; Clinical Science Symposium: Lymphoma and Plasma Cell Disorders Elotuzumab in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I Study
- Dr. A.J. Jakubowiak, University of Michigan, Ann Arbor
- Abstract #8003
- 4:30-6:00 p.m., E354a
Sunday, June 6, 2010; Oral Abstract Session Elotuzumab in Combination with Lenalidomide and Low-dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase I/II Study
- Dr. S. Lonial, Winship Cancer Institute of Emory University, Atlanta
- Abstract #8020
- 9:30 a.m.- 12:30p.m.., E354b
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Consortium (MMRC) is a 509(a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University.
The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in today's most promising research areas–genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit: www.themmrc.org.
Media Contact: Terri Clevenger, 203-227-0209, email@example.com